Illicit peptides slip through gaps in US drug policy

Clinical takeaway: Be aware that peptides often sit outside reliable safety evidence, and patients accessing them online may not disclose use unless asked.

Synthetic peptides are emerging as the next frontier in enhancement drug use, promoted online for muscle growth, recovery, and antiaging. The problem for clinicians and regulators, a new JAMA Viewpoint argues, is structural: these compounds don't behave like conventional drugs. Adoption is occurring across various pathways including FDA-approved therapeutic markets, legal compounding pathways, and unregulated illicit channels. That blurs the line between treatment and enhancement, leaving existing US drug policy poorly aligned with how peptides are actually accessed.

Awareness of peptides appears highest among younger people, particularly adolescent boys and young men exposed to social media body ideals. The scale is hard to ignore: peptide-related hashtags exceeded 130,000 Instagram posts and 230 million TikTok views as of May 2026, where influencer content and direct-to-consumer supply chains create low-friction paths to access.

Injectable compounds such as BPC-157 are marketed for muscle growth and recovery, though preliminary evidence raises concerns including pathologic angiogenesis and toxic metabolites, and human data remain limited. BPC-157 has been evaluated mainly in animal and lab studies for musculoskeletal healing, with no approved clinical indication. The authors situate this within a broader cultural push toward pharmacological self-optimization.

What makes peptides hard to govern is that they don't sit in one regulatory category. The same compound can exist as an approved medicine, a compounded therapy, a wellness product, and an illicit enhancement drug. Approved peptide medicines such as the GLP-1 receptor agonists semaglutide and tirzepatide share market space with peptides sold through telehealth clinics, compounding pharmacies, and research-chemical vendors.

Adding to the instability is a regulatory whipsaw. Several peptides, including BPC-157 and ipamorelin, have been restricted from compounding over thin clinical evidence. At the same time, US policymakers have promoted peptides for injury recovery and longevity and criticized FDA limits, with proposals under Robert F. Kennedy Jr's Make America Healthy Again platform to loosen restrictions. Substances can shift between restricted and permitted over short periods, which does not eliminate demand but may push it toward unregulated supply.

Conventional tools such as prohibition, import controls, and static scheduling target the supply chain but miss the digital ecosystems driving demand. The authors argue for more coordinated use of existing mechanisms: FDA warning letters and import alerts, FTC enforcement against deceptive influencer marketing, tighter telehealth oversight, and platform-level limits on direct-to-consumer promotion.

"Regulatory instability, digital supply chains, and blurred boundaries between therapeutics and enhancement are reshaping access and use," the authors conclude. "A parallel gap is limited research on peptide use and harms, despite the feasibility of studying these compounds. Without more adaptive, system-oriented responses, policy will remain reactive and insufficient to protect public health."

Source: Piatkowski T, et al. JAMA. 2026 Jun 15. Illicit injectable peptides and regulatory gaps